Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, December 17, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) expressed its support for the recommendation of the Task Force on Climate-related Financial Disclosures*1 (TCFD), established by the Financial...
TOKYO, December 16, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that Astellas will open a new logistics center for the Kyushu area in Kitakyushu City, Fukuoka Prefecture...
PITTSBURGH, PA and TOKYO, December 7, 2020 – KaliVir Immunotherapeutics LLC (CEO: Helena Chaye, Ph.D., J.D., “KaliVir”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that they entered...
TOKYO, December 7, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) announced that the two companies have agreed to end the joint...
TOKYO, November 27, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the subsidiary Astellas Pharma Europe Ltd. (“Astellas Europe”) and Tillotts Pharma AG (“Tillotts”) have entered into an...
Follow us
